1. Home
  2. ASA vs OCS Comparison

ASA vs OCS Comparison

Compare ASA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASA
  • OCS
  • Stock Information
  • Founded
  • ASA 1958
  • OCS 2003
  • Country
  • ASA United States
  • OCS Switzerland
  • Employees
  • ASA N/A
  • OCS N/A
  • Industry
  • ASA Precious Metals
  • OCS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASA Industrials
  • OCS Health Care
  • Exchange
  • ASA Nasdaq
  • OCS Nasdaq
  • Market Cap
  • ASA 905.1M
  • OCS 1.0B
  • IPO Year
  • ASA N/A
  • OCS N/A
  • Fundamental
  • Price
  • ASA $51.27
  • OCS $18.81
  • Analyst Decision
  • ASA
  • OCS Strong Buy
  • Analyst Count
  • ASA 0
  • OCS 5
  • Target Price
  • ASA N/A
  • OCS $39.80
  • AVG Volume (30 Days)
  • ASA 79.2K
  • OCS 132.8K
  • Earning Date
  • ASA 12-09-2025
  • OCS 11-10-2025
  • Dividend Yield
  • ASA 0.12%
  • OCS N/A
  • EPS Growth
  • ASA 335.96
  • OCS N/A
  • EPS
  • ASA 19.90
  • OCS N/A
  • Revenue
  • ASA $3,982,215.00
  • OCS $991,999.00
  • Revenue This Year
  • ASA N/A
  • OCS $32.89
  • Revenue Next Year
  • ASA N/A
  • OCS $1,043.16
  • P/E Ratio
  • ASA $2.56
  • OCS N/A
  • Revenue Growth
  • ASA 99.75
  • OCS N/A
  • 52 Week Low
  • ASA $19.37
  • OCS $14.00
  • 52 Week High
  • ASA $53.76
  • OCS $23.08
  • Technical
  • Relative Strength Index (RSI)
  • ASA 63.42
  • OCS 41.08
  • Support Level
  • ASA $45.79
  • OCS $19.07
  • Resistance Level
  • ASA $49.33
  • OCS $19.43
  • Average True Range (ATR)
  • ASA 1.94
  • OCS 0.45
  • MACD
  • ASA 0.22
  • OCS -0.05
  • Stochastic Oscillator
  • ASA 95.08
  • OCS 10.75

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Share on Social Networks: